<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01910090</url>
  </required_header>
  <id_info>
    <org_study_id>FAFL439/PRO-00</org_study_id>
    <nct_id>NCT01910090</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET in Healthy Subjects Under Fasting Conditions</brief_title>
  <official_title>Comparative, Randomized, Two-period, Two-treatment, Two-sequence, Single Dose, Open-label, Crossover Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET (One Tablet) of (Sanovel İlaç San. ve Tic. A.Ş., İstanbul / Türkiye) Versus ANTADYS® Flurbiprofen 100 mg Comprimé Pelliculé (One Film-coated Tablet) of (LaboratoireThẻramex 6, Avenue Albert II- BP.59 98007 MONACO Cedex) and PEPCID® (Famotidine) 20 mg Tablets, USP (One Tablet) of (Marathon Pharmaceuticals, LLC USA) in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaceutical Research Unit, Jordan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmaceutical Research Unit, Jordan</source>
  <brief_summary>
    <textblock>
      To assess the bioequivalence of Test oral formulation of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg
      MULTI-LAYER TABLET versus Reference ANTADYS®100 mg Comprimé Pelliculé &amp; PEPCID® (Famotidine)
      20mg Tablets, USP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, single dose, two-treatment, two-period, two-sequence, crossover
      bioequivalence with a washout period of at least 7 days between doses Healthy mixed skin Arab
      &amp; Mediterranean Subjects ages between 18 and 45 years, body-mass index 18.5 to 30.0 kg/m2
      inclusive, non-smokers or light smokers (smokers of not more than 10 cigarettes per day).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cmax</measure>
    <time_frame>five weeks</time_frame>
    <description>Cmax Ratio: The 90% confidence interval for this measure lies within an acceptance range of 80.00% - 125.00% based on Flurbiprofen and Famotidine.
AUC Ratio: The 90% confidence interval for this measure lies within an acceptance range of 80.00% - 125.00% based on Flurbiprofen and Famotidine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax</measure>
    <time_frame>three weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FLURBIPROFEN, FAMOTIDINE 100/20 mg MULTI-LAYER TABLET one tablet, once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANTADYS® and PEPCID®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET</intervention_name>
    <description>MULTI-LAYER TABLET</description>
    <arm_group_label>FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET</arm_group_label>
    <other_name>MULTI-LAYER TABLET</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANTADYS® 100 mg, PEPCID® 20 mg</intervention_name>
    <description>ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once</description>
    <arm_group_label>ANTADYS® and PEPCID®</arm_group_label>
    <other_name>ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Male subjects.

          2. Ethnic Group: Arab &amp; Mediterranean

          3. Race: Mixed skin (white &amp; black skin people).

          4. Age 18-45 years

          5. Body-mass index 18.5 to 30.0 kg/m2 inclusive

          6. Subject is available for the whole study period and gave written informed consent

          7. Physical examination within normal ranges

          8. All laboratory screening results within the normal range, or being assessed as
             clinically non-significant by the attending physician.

          9. Vital signs within normal ranges (Unless clinical investigator classified as
             insignificant).

         10. Normal Kidney &amp; Liver function tests (Unless clinical investigator classified as
             insignificant).

         11. Normal Cardiovascular system.

         12. Normal Digestive system.

        Exclusion Criteria:

          1. Women.

          2. Ethnic Group (Non- Arab &amp;/ or Non- Mediterranean)

          3. History of severe allergy or allergic reactions to study drug or related drugs

          4. Known history or presence of food allergies, or any condition known to interfere with
             the absorption, distribution, metabolism or excretion of drugs

          5. History of serious illness that can impact fate of drugs

          6. Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine,
             musculoskeletal, neurological, hematological, liver or kidney disease, unless judged
             not clinically significant by the Principal Investigator, or medical designate

          7. Clinically significant illness 4 weeks before study Period I

          8. Mental disease, drug, alcohol, solvents or caffeine abuse, smoking.

          9. Regular use of medication

         10. Having taken medication that could affect the investigated drug product: a) Regular
             consumption of drugs during the two weeks prior to study initiation day, b)
             consumption of enzyme stimulating or inhibiting drugs (e.g. Barbiturates,
             Carbamazepine, Phenytoin) during one month before the study initiation.

         11. Presence of any significant physical or organ abnormality

         12. Donation of 1) at least 400 ml of blood within 60 days, or 2) more than 150 ml of
             blood within 30 days, or 3) more than 100 ml blood plasma or platelets within 14 days
             before study Period I

         13. Participation in another bioequivalence study within 80 days prior to the start of
             this study Period I

         14. Following a special diet (e.g. vegetarian) or dieting one month before the study
             initiation.

         15. History of Gastrointestinal diseases

         16. Prior history of hypersensitivity to Flurbiprofen or Famotidine and other competitive
             inhibitor of histamine H2-receptors.

         17. Consumption of grapefruit or grapefruit containing products within 7 days of drug
             administration

         18. Ingestion of any vitamins or herbal products within 7 days prior to the initial dose
             of the study medication.

         19. Exhausting physical exercise in the last 48 hours (e.g. weight lifting) or any recent
             significant change in dietary or exercise habits.

         20. Any significant clinical abnormality including HBsAg, HCV, and HIV

         21. Abnormal vital signs

         22. Abnormal Kidney or Liver function tests.

         23. Abnormal Cardiovascular system.

         24. Abnormal Digestive system

         25. Vomiting, Diarrhea.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Rana T. Bustami, Ph.D. of Pharmacy</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRU</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Rana T. Bustami, Ph.D. of Pharmacy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Rana T. Bustami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit</name>
      <address>
        <city>Amman</city>
        <zip>00962</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <last_update_submitted>July 24, 2013</last_update_submitted>
  <last_update_submitted_qc>July 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fasting condition</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famotidine</mesh_term>
    <mesh_term>Flurbiprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

